For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240311:nRSK4189Ga&default-theme=true
RNS Number : 4189G Smith & Nephew Plc 11 March 2024
SMITH & NEPHEW PLC
11 March 2024
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE
EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.
1. AWARDS MADE UNDER THE DEFERRED SHARE BONUS PLAN
On 8 March 2024, the following awards of US$0.20 ordinary shares (the
"Shares") in Smith & Nephew plc (the "Company") were granted under the
Company's Deferred Share Bonus Plan. The awards have been made in London and
are based on the closing Share price on the London Stock Exchange on 7 March
2024 of £10.875.
A portion (50%) of the annual bonus earned by the following Executive
Directors for performance during the year to 31 December 2023 has been
deferred into share awards. The awards will normally vest on 8 March 2027
(subject to continued achievement of objectives and employment). The Executive
Directors will be required to hold the shares (after tax) for a further period
of two years to 8 March 2029. The Executive Directors will receive an
additional number of shares equivalent to the amount of dividend payable per
vested share during the relevant vesting period.
The following relates to individuals included in the below notification:
Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc Ordinary Shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Awards granted on 8 March 2024 under the Smith & Nephew plc Deferred Share
Bonus Plan.
Date of Transaction 2024 - 03 - 08
Place of Transaction Grant took place outside a trading venue
Name Status Price (s) Volume(s) Aggregated information
(Position)
Deepak Nath Director £10.875 72,005 N/A Single Transaction
(Chief Executive Officer)
Anne-Françoise Nesmes Director £10.875 37,368 N/A Single Transaction
(Chief Executive Officer)
2. AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020
On 8 March 2024, the following awards of US$0.20 ordinary shares (the
"Shares") in Smith & Nephew plc (the "Company") were granted under the
Smith & Nephew Global Share Plan 2020. The awards have been made in London
and are based on the closing Share price on the London Stock Exchange on 7
March 2024 of £10.875.
i. DEFERRED BONUS PLAN AWARDS GRANTED UNDER THE SMITH &
NEPHEW GLOBAL SHARE PLAN 2020:
A portion of the annual bonus earned by the following PDMRs for performance
during the year to 31 December 2023 has been deferred into share awards. These
awards will normally vest in equal annual tranches over three years following
the award date, subject to continued achievement of objectives and employment.
In the event that objectives are not met in any of the three years, the
portion of shares due to vest on the following anniversary will lapse. PDMRs
will receive an additional number of shares equivalent to the amount of
dividend payable per vested share during the relevant vesting period.
The following relates to individuals included in the below notification:
Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc Ordinary Shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Deferred Bonus Plan awards granted on 8 March 2024 under the Smith &
Nephew Global Share Plan 2020.
Date of Transaction 2024 - 03 - 08
Place of Transaction Grant took place outside a trading venue
Name Status Price (£) Volume Aggregated information
(Position)
Helen Barraclough PDMR £10.875 9,366 N/A Single Transaction
(Group General Counsel and Company Secretary)
Paul Connolly PDMR £10.875 9,849 N/A Single Transaction
(President, Global Operations)
Phil Cowdy PDMR £10.875 10,093 N/A Single Transaction
(Chief Corporate Development and Corporate Affairs Officer)
Craig Gaffin PDMR £10.875 5,572 N/A Single Transaction
President, Global Orthopaedics
Rohit Kashyap PDMR £10.875 11,031 N/A Single Transaction
(President AWM and Global Commercial Operations)
Mizanu Kebede PDMR £10.875 11,327 N/A Single Transaction
(Chief Quality & Regulatory Affairs Officer)
Elga Lohler PDMR £10.875 14,129 N/A Single Transaction
(Chief HR Officer)
Vasant Padmanabhan PDMR £10.875 14,214 N/A Single Transaction
(President Research & Development ENT)
Alison Parkes PDMR £10.875 5,474 N/A Single Transaction
(Chief Compliance Officer)
Scott Schaffner PDMR £10.875 17,652 N/A Single Transaction
(President Sports Medicine)
ii. PERFORMANCE SHARE PROGRAMME 2024 AWARDS GRANTED UNDER THE
SMITH & NEPHEW GLOBAL SHARE PLAN 2020
The Remuneration Committee has approved performance conditions attached to the
vesting of these awards, which are detailed below. These awards will vest on 8
March 2027, subject to the achievement of the performance conditions which are
measured over the period 1 January 2024 to 31 December 2026 as set out below.
The number of shares subject to the above awards are shown at target vesting.
Should maximum vesting be achieved, participants will receive twice the number
of shares shown below. Participants will receive an additional number of
shares equivalent to the amount of dividend payable per vested share during
the relevant performance period.
The following relates to all individuals included in this section:
Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc Ordinary Shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Performance Share Awards granted at target on 8 March 2024 under the Smith
& Nephew Global Share Plan 2020.
Date of Transaction 2024 - 03 - 08
Place of Transaction Grant took place outside a trading venue
Name Status Price (£) Volume Aggregated information
(Position)
Helen Barraclough PDMR £10.875 35,803 N/A Single Transaction
(Group General Counsel and Company Secretary)
Paul Connolly PDMR £10.875 43,926 N/A Single Transaction
(President, Global Operations)
Phil Cowdy PDMR £10.875 38,581 N/A Single Transaction
(Chief Corporate Development and Corporate Affairs Officer)
Craig Gaffin PDMR £10.875 70,920 N/A Single Transaction
President, Global Orthopaedics
Rohit Kashyap PDMR £10.875 98,357 N/A Single Transaction
(President AWM and Global Commercial Operations)
Mizanu Kebede PDMR £10.875 45,088 N/A Single Transaction
(Chief Quality & Regulatory Affairs Officer)
Elga Lohler PDMR £10.875 56,239 N/A Single Transaction
(Chief HR Officer)
Deepak Nath PDMR £10.875 151,365 N/A Single Transaction
(Chief Executive Officer)
Vasant Padmanabhan PDMR £10.875 56,577 N/A Single Transaction
(President Research & Development ENT)
Alison Parkes PDMR £10.875 10,429 N/A Single Transaction
(Chief Compliance Officer)
Scott Schaffner PDMR £10.875 85,666 N/A Single Transaction
(Global President Sports Medicine)
The performance conditions applying to these awards have been determined by
the Remuneration Committee.
The awards made to the Executive Directors are subject to four performance
measures in the proportions shown:
- Total Shareholder Return (TSR) - 30%;
- Return on Invested Capital (ROIC) - 30%;
- Global Revenue Growth - 30%; and
- Environmental, Social and Governance (ESG) objectives - 10%.
The awards are subject to TSR as follows:
Award vesting as % of salary at date of grant
Sector based peer group FTSE100 peer group
Below the index Nil Nil
Equaling the index 8.6% 8.6%
8% above the index 34.4% 34.4%
Awards vest on a straight-line basis between these points. The maximum has
been set significantly above target reflecting the maximum opportunity for
outperformance.
The awards are subject to ROIC as follows:
Return on Invested Capital Award vesting as a % of salary
Year ended 31 December 2026
Below 8.5% Nil
8.5% 17.2%
9.0% 34.4%
10.5% 68.8%
Awards vest on a straight-line basis between these points.
The awards are subject to Revenue Growth as follows:
Revenue Growth Award vesting as a % of salary
Three years ended 31 December 2026
Below Threshold Nil
Threshold (-8% of target) 17.2%
Target - set by reference to our expectations 34.4%
Maximum or above (+8% of target) 68.8%
Awards vest on a straight-line basis between these points.
The awards are subject to ESG objectives which relate to the Group's strategic
priorities in this area, with primary focus on carbon reductions and diversity
measures.
Revenue Growth targets for the three years ending 31 December 2026 for these
awards, even though now determined, will not be disclosed until the 2026
Annual Report, when the Remuneration Committee will discuss performance
against the targets. It is not possible to disclose precise targets at the
time of grant to avoid giving commercially sensitive information to our
competitors concerning our growth plans.
Sarah Carne
Deputy Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477100
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFLFLTVTILLIS